<?xml version="1.0" encoding="UTF-8"?>
<p>Eltrombopag was developed as a thrombopoietin receptor agonist [
 <xref rid="B1-cells-09-00031" ref-type="bibr">1</xref>,
 <xref rid="B2-cells-09-00031" ref-type="bibr">2</xref>,
 <xref rid="B3-cells-09-00031" ref-type="bibr">3</xref>]. However, it is unlikely that eltrombopag inhibits HCMV replication via thrombopoietin receptor activation, because fibroblasts do not express the thrombopoietin receptor [
 <xref rid="B28-cells-09-00031" ref-type="bibr">28</xref>]. In agreement, eltrombopag also inhibited murine cytomegalovirus replication in murine NIH/3T3 fibroblasts (
 <xref ref-type="fig" rid="cells-09-00031-f003">Figure 3</xref>A), although eltrombopag does not target the murine thrombopoietin receptor [
 <xref rid="B29-cells-09-00031" ref-type="bibr">29</xref>].
</p>
